KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events. PMID 40032221 · Am J Clin Nutr · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. PMID 40031941 · Lancet Diabetes Endocrinol · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores. PMID 40024335 · Respir Med · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Inhaled alone versus inhaled plus intravenous polymyxin B for the treatment of pneumonia due to carbapenem-resistant gram-negative bacteria: A prospective randomized controlled trial. PMID 40023452 · Int J Antimicrob Agents · 2025-May The study is a randomized controlled trial of an antibiotic (Polymyxin B) for pneumonia caused by carbapenem-resistant Gram-negative bacteria. While it includes patients with malignancies as a prognostic factor, the study is not primarily an oncology trial, its phase is not defined as definitive (III/IIIb or II/III), and it lacks the required time-to-event primary efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study). PMID 40023371 · J Allergy Clin Immunol Pract · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial. PMID 40020692 · Lancet Respir Med · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. PMID 40016055 · Eur Urol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies. PMID 40013432 · Diabetes Obes Metab · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of swab versus tissue sampling for infected diabetic foot ulcers from the CODIFI2 randomised controlled trial. PMID 40013389 · Diabet Med · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. PMID 39996356 · Diabetes Obes Metab · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials. PMID 39986927 · Ann Oncol · 2025-May The record reports on a biomarker (PORTOS) analysis from two Phase III randomized trials of prostate cancer radiotherapy. While it meets criteria for oncology, human, randomized, Phase III, and time-to-event endpoints, it fails the drug-intervention criterion as the intervention is radiation dose, not a drug. Furthermore, this is a secondary analysis/validation study of the parent trials, not the primary result report.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence. PMID 39985317 · Allergy · 2025-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm. PMID 39983751 · Lancet Rheumatol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents. PMID 39970021 · J Child Adolesc Psychopharmacol · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cognitive behavioral stress management effects on cancer-related distress and neuroendocrine signaling in breast cancer: differential effects by neighborhood disadvantage. PMID 39966311 · Breast Cancer Res Treat · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comment on: A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial. PMID 39956438 · Ann Oncol · 2025-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE. PMID 39956162 · J Allergy Clin Immunol Pract · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks Trial. PMID 39954920 · Am J Ophthalmol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes. PMID 39952901 · Eur J Haematol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials. PMID 39948001 · Ann Rheum Dis · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement. PMID 39934019 · Ann Rheum Dis · 2025-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. PMID 39928262 · Breast Cancer Res Treat · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study. PMID 39927501 · Am J Hematol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Characterization of the effect of naltrexone/bupropion on body composition. PMID 39927409 · Diabetes Obes Metab · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Radiotherapy quality assurance for the PEACE 1 trial: An individual case review analysis. PMID 39924002 · Radiother Oncol · 2025-May The record describes a radiotherapy quality assurance sub-study of the PEACE-1 Phase III trial, focusing on protocol compliance for RT plan delineation and dosimetry. It does not report on any time-to-event efficacy endpoints (e.g., OS, PFS) or survival analysis (Kaplan-Meier, HR).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The positive impact of an internet-based post-diagnosis disease management model on patients undergoing opportunistic screening for upper gastrointestinal cancer: A randomized controlled trial. PMID 39919618 · Patient Educ Couns · 2025-May The trial is a randomized controlled trial in oncology patients but does not meet key eligibility criteria: it is not a Phase III or II/III trial, it lacks a drug-containing intervention, and its primary endpoint is not a time-to-event efficacy measure.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials. PMID 39903903 · J Clin Oncol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
How we diagnose and manage refractory and resistant herpes simplex virus mucocutaneous infection after haematopoietic cell transplantation. PMID 39900291 · Clin Microbiol Infect · 2025-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies. PMID 39884760 · Eur Respir J · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Triaging mammography with artificial intelligence: an implementation study. PMID 39881074 · Breast Cancer Res Treat · 2025-May The study is an oncology RCT with original results, but it is not a Phase III/definitive drug trial and its primary endpoints are operational time-to-diagnosis metrics, not time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials. PMID 39848335 · Ann Oncol · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
An Artificial Intelligence-Digital Pathology Algorithm Predicts Survival After Radical Prostatectomy From the Prostate, Lung, Colorectal, and Ovarian Cancer Trial. PMID 39841869 · J Urol · 2025-May The study is a prognostic/biomarker analysis (AI pathology algorithm) applied to a subset of patients from a randomized screening trial. It does not evaluate a drug-containing intervention in a definitive phase trial with a primary/key secondary time-to-event efficacy endpoint for that intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study. PMID 39824198 · Lancet Infect Dis · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis. PMID 39823276 · Eur J Heart Fail · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients. PMID 39808288 · Clin Exp Rheumatol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis. PMID 39808286 · Clin Exp Rheumatol · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population. PMID 39805350 · Ann Oncol · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Albendazole-ivermectin co-formulation for the treatment of Trichuris trichiura and other soil-transmitted helminths: a randomised phase 2/3 trial. PMID 39805305 · Lancet Infect Dis · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA). PMID 39732365 · J Thorac Oncol · 2025-May The record is excluded because it is a non-randomized, single-center pilot study, not a randomized Phase III/IIIb or Phase II/III trial as required. While it is an oncology human study with a drug intervention and reports DFS data, the lack of randomization and definitive phase (the study is described as a pilot, and publication types include Phase I/II) makes it ineligible for the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Digoxin vs Beta-Blockers on Left Atrial Strain for Heart Rate-Controlled Atrial Fibrillation: The DIGOBET-AF Randomized Clinical Trial. PMID 39725795 · Am J Cardiovasc Drugs · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis. PMID 39698868 · United European Gastroenterol J · 2025-May The record is not oncology and does not have a time-to-event efficacy endpoint, making it ineligible for the oncology Kaplan-Meier digitization cohort.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10-12 years: phase III randomized trial complementary analysis of immune persistence 3-6 years after priming. PMID 39672823 · Pediatr Res · 2025-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H L
旧查询独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A relook at the relevance of thyroid stimulating hormone and thyroid autoimmunity for pregnancy outcomes: Analyses of randomized control trials data from Pregnancy in Polycystic Ovary Syndrome and Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation. PMID 39672366 · Fertil Steril · 2025-May 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Procalcitonin-guided use of antibiotic in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized clinical trial. PMID 39662822 · Clin Microbiol Infect · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial. PMID 39647494 · Lancet Infect Dis · 2025-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Study on the role of postoperative rehabilitation based on the ERAS concept for patients undergoing pancreaticoduodenectomy: Protocol for a randomized controlled clinical trial. PMID 39642276 · Adv Clin Exp Med · 2025-May The record is a protocol for a randomized controlled trial. It is a study plan, not a formal result report. The trial assesses a postoperative rehabilitation program (non-drug intervention) after pancreaticoduodenectomy for cancer, but the primary endpoint is cardiopulmonary capacity (6-minute walk test), and secondary endpoints are quality of life and recovery metrics, not a time-to-event efficacy endpoint. No drug intervention is present. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Erzhu Jiedu Decoction Granules in Treating Mid-advanced Hepatitis B Virus-Associated Primary Liver Cancer Patients with Pi (Spleen)-Deficiency and Dampness-Heat Syndrome. PMID 39636494 · Chin J Integr Med · 2025-May The study is a randomized oncology trial with a primary time-to-event endpoint (PFS) and reports original results. However, it is excluded because the intervention is a traditional Chinese herbal medicine preparation, not a standard oncology drug as required by the cohort criteria, and the trial phase is not explicitly reported in the metadata to confirm it is Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. PMID 39632125 · Eur Urol · 2025-May The trial is nonrandomized and compares two non-drug interventions (HIFU vs. radical prostatectomy). It therefore fails two mandatory inclusion criteria: randomized trial design and a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration. PMID 39617060 · Ophthalmology · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A post hoc analysis of migraine-associated symptoms from the phase 3 randomized, double-blind, sham-controlled Trial of External trigeminal nerve stimulation for the Acute treatment of Migraine (TEAM) study. PMID 39601100 · Headache · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -